Haohai Biological Technology

What Haohai Biological Technology does

Haohai Biological Technology (Shanghai Haohai Biological Technology Co., Ltd., 06826.HK / 688366.SH) is a Shanghai-headquartered biopharmaceutical company founded in 2007 and dual-listed on the Hong Kong Stock Exchange (April 2015) and the Shanghai Stock Exchange STAR Market (October 2019), making it the first H+STAR Market biopharmaceutical enterprise in China. The company is vertically integrated across the full biomedical materials value chain, from raw-material production (the only China manufacturer with both cockscomb extraction and fermentation-method approvals for sodium hyaluronate API) through R&D, manufacturing, and sales, organized around four therapeutic areas: ophthalmology, medical aesthetics and wound care, orthopedics, and anti-adhesion and hemostasis.

Its core technology platform spans proprietary hyaluronic acid cross-linking chemistry (four successive generations of dermal fillers 海薇/姣兰/海魅/海魅月白, with the fourth using world-first lysine organic cross-linking), medical chitosan technology (the only Class III-registered intra-articular injection for orthopedic joint cavity viscoelastic supplementation in China, awarded the National Science and Technology Progress Award Second Prize in 2009), the world's first approved recombinant human epidermal growth factor product (rhEGF, Class I new drug 2001), and intraocular lens manufacturing using self-developed hydrophobic mold-casting processes (Toric IOL ST1~ST7, patent ZL2022117178044). The product portfolio includes 25+ medical devices and pharmaceuticals sold under brands such as 海薇, 海魅, 海视盈, 奇特杰, 赛美视, 童享, 亨泰, 依镜, EndyMed, and 康合素.

The company operates a sales-led go-to-market through direct field sales to hospitals, clinics, and medical aesthetics institutions across China, supplemented by channel partnerships and exclusive distribution agreements for OK lenses (Hengtai, Tongxiang), PRL refractive lenses (Yijing), and US Valley Contax scleral contact lenses (via the 2024 acquisition of 51% of Shanghai Shinhao). Strategic partnerships include the 2021 Eirion equity-and-licensing deal for botulinum toxin and ET-02 hair-loss candidates in Greater China, and the 2024 UCL Global Health Business School co-creation. International footprint is anchored by UK-based Contamac (high oxygen-permeable contact lens materials with FDA approval) and Israel-based EndyMed (RF aesthetic devices). 2025 revenue was 24.73亿 RMB with 2.51亿 RMB net profit, and the company maintained the #1 China position in ophthalmic viscoelastic agents (51.42% share), surgical anti-adhesion agents (25.87% share), and orthopedic joint cavity viscoelastic supplements (44.43% share).

Name

Haohai Biological Technology

Legal name

上海昊海生物科技股份有限公司

Website

https://3healthcare.com

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Haohai Biological Technology is a Chinese dual-listed biopharmaceutical manufacturer of biomedical materials (hyaluronic acid, chitosan, intraocular lenses, rhEGF) serving ophthalmology, medical aesthetics, orthopedics, and surgical markets, with leading domestic market positions across multiple product categories.

Ownership category

akta.pro rank

Product category

Biomedical Materials and Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates) (IMAEAOAL)

Keywords

• Biomedical materials
• Hyaluronic acid products
• Intraocular lenses
• Ophthalmic medical devices
• Dermal fillers

Headquarters

HQ city

Changning

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales

Revenue model

1. Medical Devices and Pharmaceuticals Sales: The company generates revenue through the manufacturing and sales of biomedical materials and medical devices across four therapeutic areas: ophthalmology, medical aesthetics and wound care, orthopedics, and anti-adhesion and hemostasis. Products include intraocular lenses, hyaluronic acid dermal fillers, sodium hyaluronate injections, medical chitosan, collagen sponges, and other medical devices sold directly to hospitals and clinics.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Haohai Biological Technology (Shanghai Haohai Biological Technology Co., Ltd.) researches, manufactures, and sells biomedical materials and medical devices across four therapeutic areas: ophthalmology (intraocular lenses, viscoelastic agents, ortho-K lenses, eye drops), medical aesthetics and wound care (hyaluronic acid dermal fillers, recombinant human epidermal growth factor, RF aesthetic devices), orthopedics (sodium hyaluronate and medical chitosan intra-articular injections), and anti-adhesion and hemostasis (sodium hyaluronate gels, collagen sponges, fibrin sealants). The company operates full-industry-chain integration from raw materials (HA, chitosan) through R&D, manufacturing, and sales.

Product overview

Haohai Biological Technology is a biopharmaceutical company specializing in biomedical materials with a diversified product portfolio spanning four therapeutic areas: ophthalmology, medical aesthetics & wound care, orthopedics, and anti-adhesion & hemostasis. In ophthalmology, the company offers a comprehensive intraocular lens portfolio including brands like Henan Universe, Zhuhai Eyegood, Aaren, and Hexavision (self-produced), along with Lenstec (distributed), as well as ortho-K lenses (Tongxiang, Hengtai/Hiline), viscoelastic agents,润眼液, and moxifloxacin eye drops. In medical aesthetics, the company markets three generations of hyaluronic acid dermal fillers under the brands 海薇 (Matrifill), 姣兰 (Jiaolan), and 海魅 (Hai Mei/Haimi), plus human epidermal growth factor (康合素). In orthopedics, the company offers sodium hyaluronate injections and medical chitosan intra-articular injections. In anti-adhesion & hemostasis, the company provides sodium hyaluronate gels, medical chitosan, collagen sponges, and porcine fibrin sealants. The company has achieved full industry chain integration from raw materials to R&D, manufacturing, and sales, and was the first 'H+ STAR Market' biopharmaceutical company listed on both Hong Kong Stock Exchange (06826.HK) and Shanghai Stock Exchange STAR Market (688366.SH).

Differentiator

Problem solved

Functional benefit

Brands

• 海薇 (Matrifill): First generation cross-linked sodium hyaluronate gel dermal filler for facial wrinkle correction
• 姣兰 (Jiao Lan/Janlane)
• 海魅 (Hai Mei/Hyalumatrix)
• 海魅月白 (Hai Mei Yuebai)
• 海视盈 (Haishiying)
• 其胜 (Qisheng)
• 适唯可 (Shiweike)
• 眼舒康 (Yanshukang/Eyesucom)
• 海莫西 (Haimoxi)
• 康合素 (Kanghesu)
• 童享 (Tongxiang/Optoshare)
• 亨泰 (Hengtai/Hiline)
• 依镜 (Yijing/PRL)
• 贝视得 (Beishide)
• 河南宇宙 (Henan Universe)
• 赛美视 (Saimeshi)
• 奇特杰/奇特邦 (Qitejie/Qitebang)
• 康瑞胶 (Kangruijiao)
• EndyMed
• myOK/迈儿康
• CS巩膜镜

Products and services

• Haishukang Medical Sodium Hyaluronate Gel (Anti-adhesion) (海术康®医用透明质酸钠凝胶（防粘连）) Medical sodium hyaluronate gel used to prevent or reduce post-operative adhesions in abdominal/pelvic cavity surgeries, sold to hospitals and surgical institutions.
• Haishiying Medical Sodium Hyaluronate Gel (Ophthalmic Viscoelastic) (海视盈®医用透明质酸钠凝胶（眼科用粘弹剂）) Medical sodium hyaluronate gel used as ophthalmic viscoelastic device during eye surgeries to maintain anterior chamber space and protect eye tissues, sold to ophthalmic surgical hospitals.
• Tongxiang Orthokeratology Rigid Gas Permeable Contact Lens (童享角膜塑形用硬性透气接触镜) Orthokeratology rigid gas permeable contact lens for temporary correction of myopia in children and adolescents with myopia degrees from -1.00D to -4.00D, sold to ophthalmology clinics and hospitals.
• Yijing PRL Phakic Posterior Chamber Refractive Lens (依镜®PRL有晶体眼后房屈光晶体) Posterior chamber refractive lens for phakic eyes, indicated for myopic patients aged 20-50 with myopia from -10.0D to -30.0D, sold to ophthalmic surgical centers.
• Hengtai Orthokeratology Rigid Gas Permeable Contact Lens (亨泰角膜塑形用硬性透气接触镜) Hengtai/Hiline brand orthokeratology rigid gas permeable contact lens for temporary myopia correction with water content less than 1%, sold to ophthalmology clinics.
• Beishide Myopia Control Spectacle Lenses for Children (贝视得™青少年儿童视力防控框架镜) Myopia control spectacle lenses for children and adolescents with myopic refractive errors to improve naked eye vision, sold through optical retail and clinical channels.
• Lenstec SBL-3 Segmental Refractive Multifocal Intraocular Lens (新产业 Lenstec®区域折射多焦人工晶状体) Lenstec SBL-3 segmental refractive multifocal intraocular lens for patients over 18 years old undergoing cataract surgery, distributed to ophthalmic hospitals and surgical centers.
• Henan Universe Foldable Intraocular Lens (河南宇宙折叠式人工晶体) Henan Universe foldable intraocular lens (PCF60, PCF60A) for implantation after cataract extraction to correct aphakia, sold to ophthalmic surgical hospitals.
• Saimishi Hydrophobic Acrylic Aspheric Intraocular Lens (赛美视®非球面疏水性丙烯酸酯人工晶状体) Saimishi hydrophobic acrylic aspheric intraocular lens (SM60AS) for posterior chamber implantation after cataract surgery, including toric IOL products.
• AAREN Hydrophilic Acrylic Aspheric Intraocular Lens (AAREN®亲水性丙烯酸酯非球面人工晶状体)

Quantifiable outcome

• 18 consecutive years as China's #1 ophthalmic viscoelastic agent producer with 51.42% market share (2024)
• +6 more outcomes

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Five partnerships are on record, tiered strategic, core and minor.

• UCL (University College London) Global Health Business SchoolstrategicStrategic or Co-development Partner · 22 November 2024Haohai partnered with UCL London to co-create the first medical aesthetics business school - UCL Global Health Business School, inaugurated at the 2024 International Forum. The partnership aims to provide comprehensive and professional exchange platforms for China's medical aesthetics industry.
• Meilai Group, Langzi Group, Yixing Group, Ruili Group, and 22 other medical aesthetics institutionscoreChannel Partner/ Reseller/ Distributor · 22 November 2024Elite institution strategic partnership program for the launch of 海魅月白 (Hyalumatrix Yuebai) amino acid cross-linked hyaluronic acid filler. First batch of 22+ medical aesthetics institutions including Meilai Group, Langzi Group, Yixing Group, Ruili Group signed as strategic partnership institutions.
• Guodong Changsha (国控长沙)minorChannel Partner/ Reseller/ Distributor · 1 October 2022Haohai's medical aesthetics product line entered into a strategic cooperation with Guodong Changsha for distribution of aesthetic medical products in the Hunan region.
• Eirion Therapeutics Inc.coreStrategic or Co-development Partner · 1 March 2021In March 2021, Haohai signed an equity investment agreement and product licensing agreement with US-based Eirion. Eirion granted Haohai exclusive rights for R&D, sales, commercialization (including packaging) of ET-01 (topical botulinum toxin type A), AI-09 (injectable botulinum toxin type A), and ET-02 (small molecule drug for hair loss and graying) in mainland China, Hong Kong, Macau, and Taiwan. Haohai has invested in Eirion. ET-02's first human clinical trial for androgenetic alopecia showed successful results in 2024.
• Shanghai Changzheng Hospital, Shanghai Ninth People's Hospital, Shanghai Sixth People's Hospital, Donghua University, Shanghai Jiao Tong University, East China University of Science and TechnologystrategicStrategic or Co-development Partner · 1 January 2021Long-term partnerships with multiple universities and research institutions for joint postdoctoral training programs and collaborative research in biomaterials and ophthalmology fields.

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Bloomage Biotechnology: Leading Chinese hyaluronic acid raw material and finished product manufacturer with a broad portfolio of HA-based skincare, medical aesthetics, and pharmaceutical products; directly competes with Haohai across both HA dermal fillers and upstream HA supply.
• Imeik Technology Development: Chinese medical aesthetics company specializing in injectable products including HA-based dermal fillers and regenerative biomaterials; directly competes with Haohai in China's premium HA filler market.
• Huadong Medicine: Chinese pharmaceutical and medical aesthetics conglomerate that acquired Sinclair Pharma; directly competes with Haohai in HA-based dermal fillers and aesthetic injectables through the Sinclair portfolio.
• STAAR Surgical: Specialty ophthalmic company focused on implantable collamer lenses (ICL) for refractive correction; directly comparable to Haohai's PRL (posterior chamber refractive lens) franchise for high myopia patients.
• Seikagaku Corporation: Japanese specialty pharmaceutical company with sodium hyaluronate-based products for joint disease and ophthalmology; closely comparable to Haohai's orthopedic HA injection and ophthalmic viscoelastic segments.

Broad incumbents

• Galderma: Global dermatology and medical aesthetics leader (owner of Restylane and other HA filler brands); competes with Haohai in the premium HA filler segment globally and increasingly in China through its direct China presence.
• AbbVie (Allergan Aesthetics): Owner of Juvéderm HA fillers, Botox, and CoolSculpting; the dominant medical aesthetics platform globally and a key competitive benchmark for Haohai's premium HA filler business.
• Alcon: Global leader in eye care including intraocular lenses, viscoelastic devices, and surgical ophthalmic products; directly competes with Haohai in IOLs and ophthalmic viscosurgical devices, especially in China.
• Carl Zeiss Meditec: Major ophthalmic medical technology company with IOL, surgical microscope, and diagnostic portfolios; competes with Haohai's intraocular lens business in cataract and refractive surgery globally.
• Bausch + Lomb: Global eye health company with IOLs, ophthalmic surgical devices, and contact lens products; competes with Haohai across multiple ophthalmology subsegments including intraocular lenses and surgical viscoelastics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Haohai Biological Technology